# Sorafenib + mFOLFOX for Hepatocellular Carcinoma

> **NCT01775501** · PHASE2 · COMPLETED · sponsor: **Massachusetts General Hospital** · enrollment: 40 (actual)

## Conditions studied

- Hepatocellular Cancer

## Interventions

- **DRUG:** Leucovorin
- **DRUG:** Fluorouracil
- **DRUG:** Oxaliplatin
- **DRUG:** Sorafenib

## Key facts

- **NCT ID:** NCT01775501
- **Lead sponsor:** Massachusetts General Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2018-07
- **Final completion:** 2019-12
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2020-04-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01775501

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01775501, "Sorafenib + mFOLFOX for Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01775501. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*